Case Study: Pre-Revenue Life Sciences Company Raises $60M via Reg A+

Posted by Life Science Intelligence on Aug 11, 2021 10:53:04 AM
Find me on:

Regulation A+ allows companies to raise up to $75M per year from both accredited and non-accredited investors. A common question founders have is whether it is really possible for a life sciences company to do raises of that size via Reg A+, especially if they’re pre-revenue, even pre-clinical. And the answer is yes.

Emerald Health Pharmaceuticals (EHP) is a clinical-stage biopharmaceutical company focused on developing a new class of proprietary molecules targeting neurodegenerative and autoimmune diseases, including multiple sclerosis, Parkinson’s, and Huntington’s. They have completed Phase I clinical trials and are enrolling for Phase IIa.

They filed their Reg A+ in March 2018 (press release / offering circular), offering 10 million shares at $5/share, for the maximum allowable raise at the time of $50M. Note that their Phase I clinical trial didn’t start until September 2018, so at the time they filed, they were not only pre-revenue, but pre-clinical.

 In 2019, they rolled into a continuous offering (which you can do every 12 months). This approach is one of the distinct advantages of Reg A+, providing the potential for an ongoing, long-term strategic capital platform. In July 2019 they amended the offering, upping the stock price to $6/share (amended offering circular). This is another advantage of Reg A+: the ability to change the offering price during the offering.

In March 2021, they announced the closing date of their offering, and that they had raised $56 million so far (press release). According to their subsequent 1-K annual report, they ended up with gross proceeds of $60 million from their Reg A+ raise.

Regulation A+ is still fairly new in the medical innovation sector. While there have been some great success stories, such as Myomo and Soliton, it’s only very recently that companies in this industry have started taking advantage of the larger amounts of capital (up to $75M a year) available with Reg A+, and to understand its benefits that make it an attractive and viable alternative to venture capital. We expect to see many more examples like this one in 2021 and 2022.

To learn more about Reg A+, schedule a call with LSI CEO Scott Pantel or Medical Funding Professionals CEO Stephen Brock

    

Stay connected with our latest posts:

About the Author

Life Science Intelligence (LSI) helps medtech executives make better strategic decisions by delivering unique market data and business insights. For over 13 years LSI has been working with industry giants – Johnson & Johnson, Medtronic, Abbott, Stryker, Cardinal, Boston Scientific, and Becton Dickinson, among others. LSI products are also leveraged by the most successful start-ups, innovators, investors, and service companies that compete in medtech. LSI is the organizer of The Emerging Medtech Summit held annually in Southern California.

Contact LSI here, via phone 714 847 3540, or email info@lsintel.com